Results 121 to 130 of about 8,062 (139)
Some of the next articles are maybe not open access.
SSRN Electronic Journal, 2022
Histological and biochemical analyses in postmortem tissues have demonstrated neurodegenerative changes in the cerebral cortex in patients with Alzheimer's disease (AD), and it has been suggested that this represents a loss of synapses. PET imaging of the (pre)synaptic vesicular glycoprotein 2A (SV2A) has demonstrated a reduction in synapse density in ...
Mikkelsen, Jens D. +3 more
openaire +4 more sources
Histological and biochemical analyses in postmortem tissues have demonstrated neurodegenerative changes in the cerebral cortex in patients with Alzheimer's disease (AD), and it has been suggested that this represents a loss of synapses. PET imaging of the (pre)synaptic vesicular glycoprotein 2A (SV2A) has demonstrated a reduction in synapse density in ...
Mikkelsen, Jens D. +3 more
openaire +4 more sources
Molecular Pharmacology, 2012
Levetiracetam (LEV) is a prominent antiepileptic drug that binds to neuronal synaptic vesicle glycoprotein 2A protein and has reported effects on ion channels, but with a poorly defined mechanism of action. We investigated inhibition of voltage-dependent Ca(2+) (Ca(V)) channels as a potential mechanism through which LEV exerts effects on neuronal ...
Sumiko Mochida +2 more
exaly +3 more sources
Levetiracetam (LEV) is a prominent antiepileptic drug that binds to neuronal synaptic vesicle glycoprotein 2A protein and has reported effects on ion channels, but with a poorly defined mechanism of action. We investigated inhibition of voltage-dependent Ca(2+) (Ca(V)) channels as a potential mechanism through which LEV exerts effects on neuronal ...
Sumiko Mochida +2 more
exaly +3 more sources
European Journal of Nuclear Medicine and Molecular Imaging, 2021
Synaptic abnormalities are associated with many brain disorders. Recently, we developed a novel synaptic vesicle glycoprotein 2A (SV2A) radiotracer [18F]SynVesT-1 and demonstrated its excellent imaging and binding properties in nonhuman primates. The aim of this study was to perform dosimetry calculations in nonhuman primates and to evaluate this ...
Songye Li +12 more
openaire +2 more sources
Synaptic abnormalities are associated with many brain disorders. Recently, we developed a novel synaptic vesicle glycoprotein 2A (SV2A) radiotracer [18F]SynVesT-1 and demonstrated its excellent imaging and binding properties in nonhuman primates. The aim of this study was to perform dosimetry calculations in nonhuman primates and to evaluate this ...
Songye Li +12 more
openaire +2 more sources
Pediatric Neurology, 2015
Synaptic vesicle protein 2A (SV2a) is the binding site of the antiepileptic drug levetiracetam and the only known synaptic vesicle target of an epilepsy medication. To date, no pathogenic mutation in SV2A, which is the gene encoding synaptic vesicle glycoprotein 2A, has been identified in humans.
Fatema J, Serajee, Ahm M, Huq
openaire +2 more sources
Synaptic vesicle protein 2A (SV2a) is the binding site of the antiepileptic drug levetiracetam and the only known synaptic vesicle target of an epilepsy medication. To date, no pathogenic mutation in SV2A, which is the gene encoding synaptic vesicle glycoprotein 2A, has been identified in humans.
Fatema J, Serajee, Ahm M, Huq
openaire +2 more sources
Glycoproteins From Adult Rat Brain Synaptic Vesicles Fractionation on Four Immobilized Lectins
Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1981A Reeber +2 more
exaly
Synaptic Vesicle Glycoprotein 2Aとてんかん
Journal of the Japan Epilepsy Society, 2018Ryosuke Hanaya, Hiroshi Hosoyama
exaly